|
|
|
|
|
|
|
|
|
Webinar: Rethinking Facility Design For The Reality Of Complex Biologics
|
As demand for complex biologics grows, integrated facility and equipment design is becoming essential to reducing risk, improving yield, and maintaining process reliability. In this webinar, experts from Jubilant HollisterStier and groninger explore how alignment across facility design, line architecture, and automation can support consistent manufacturing of complex biologics and lyophilized products, featuring JHS’s Spokane expansion as a case study. Click here to learn more.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma
|
The distance between external API producers and fill-finish experts, and the commercial apparatus of their pharma customers, has lessened. Commercial evidence now starts its derivation as innovation becomes tangible material, set processes, and then product creation … at external development and manufacturing partners. Jon Williams, CEO, Lumanity, says there's a shift toward integrating development strategy and commercial decision-making earlier in the lifecycle.
|
|
|
|
|
|
Strengthening CDMO-Sponsor Partnerships
|
|
By Muhammad Asim Niazi
|
Let's delve into the key pitfalls to avoid when working with a CDMO and the integrated execution model that solves or mitigates these pitfalls before they occur.
|
|
|
|
INDUSTRY INSIGHTS CONTINUED
|
|
|
|
|
|
|
|
De-Risking FIH: Integrated Strategies For Rapid Proof-Of-Concept
|
|
Article | By Andreas Reichl, M.D., and Kevin Schaab, Ph.D., Quotient Sciences
|
Proper planning for first-in-human studies is crucial to successful drug development, which requires innovative trial designs and sound CMC strategies to mitigate risk and expedite proof-of-concept.
|
|
|
|
|
|
Ensuring The Efficacy Of Probiotic Products
|
|
Article | Ropack Pharma Solutions
|
Without proper handling and packaging, the efficacy of probiotics can be compromised at any point in the packaging, storage, and transportation process, impacting shelf life and effectiveness.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE
|
|
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.
|
|
|
| Connect With Outsourced Pharma: |
|
|
|
|
